Injurious effect of Helicobacter pylori culture fluid to gastroduodenal mucosa, and its detoxification by sucralfate in the rat

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 10, 1999, Pages 1363-1371

  Watanabe, K ^a   Joh, T ^a   Seno, K ^a   Takahashi, N ^a   Ohara, H ^a   Nomura, T ^a   Tochikubo, K ^a   Itoh, M ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; BACTERIAL TOXIN; CHROMIUM 51; EDETIC ACID; SUCRALFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFECT; DUODENUM MUCOSA; HELICOBACTER PYLORI; INTESTINE MUCOSA; ISOTOPE LABELING; MALE; NONHUMAN; PEPTIC ULCER; PH; PRIORITY JOURNAL; RAT; STOMACH PROTECTION;

ANIMALS; ANTI-ULCER AGENTS; BACTERIAL TOXINS; CHROMIUM RADIOISOTOPES; DUODENUM; EDETIC ACID; GASTRIC MUCOSA; HELICOBACTER PYLORI; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; MALE; METABOLIC DETOXICATION, DRUG; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SUCRALFATE;

EID: 0032880069     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00600.x     Document Type: Article

References (40)

1. 1 Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-15.
2. 2 Hentschel E, Brandstatter G, Dragosies B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
3. 3 Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412-17.
4. 4 Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233-5.
5. 5 Knipp U, Birkholz S, Kaup W, Opferkuch W. Partial characterization of a cell proliferation-inhibiting protein produced by Helicobacter pylori. Infect Immun 1996; 64: 3491-6.
6. 6 Smoot DT, Resau JH, Earlington MH, Simpson M, Cover TL. Effects of Helicobacter pylori vacuolating cytotoxin on primary cultures of human gastric epithelial cells. Gut 1996; 39: 795-9.
7. 7 el Omar E, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.
8. 8 Hogan DL, Rapier RC, Dreilinger A, et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology 1996; 110: 705-16.
9. 9 Xiang Z, Censini S, Bayeli PF et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995; 63: 94-8.
10. 10 Lee A, O'Rourke J, De UM, et al. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997; 112: 1386-97.
11. 11 Leung FW. Primary sensory nerves mediate in part the protective mesenteric hyperemia after intraduodenal acidification in rats. Gastroenterology 1993; 105: 1737-45.
12. 12 Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-42.
13. 13 Smoot DT, Earlington MH, Abebe E, et al. Effects of sucralfate on vacuolating cytotoxin activity and adherence of Helicobacter pylori to human gastric epithelial cells. J Assoc Acad Minor Phys 1996; 7: 88-92.
14. 14 Smoot DT. How does Helicobacter pylori cause mucosal damage? Direct mechanisms. Gastroenterology 1997; 113: S31-4.
15. 51Cr-labelled EDTA absorption test. Lancet 1983; 1: 323-5.
16. 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318-22.
17. 17 Bjarnason T, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 2: 1171-4.
18. 51Cr-EDTA in rats with experimentally induced enteropathy. Gut 1985; 26: 579-85.
19. 19 Bjarnason I, Maxton D, Reynolds AP, et al. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol 1994; 29: 630-9.
20. 20 Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-81.
21. 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol 1987; 82: 1159-64.
22. 22 Kawai T, Joh T, Iwata F, Itoh M. Gastric epithelial damage induced by local ischemia-reperfusion with or without exogenous acid. Am J Physiol 1994; 266: G263-70.
23. 23 Seno K, Joh T, Yokoyama Y, Itoh M. Role of mucus in gastric mucosal injury induced by local ischemia/reperfusion. J Lab Clin Med 1995; 126: 287-93.
24. 24 Samloff IM, O'Dell C. Inhibition of peptic activity by sucralfate. Am J Med 1985; 79: 15-18.
25. 25 McCarthy DM. Sucralfate. N Engl J Med 1991; 325: 1017-25.
26. 26 Slomiany BL, Slomiany DA. Role of mucus in gastric mucosal protection. J Physiol Pharmacol 1991; 42: 147-61.
27. 27 Slomiany BL, Piotrowski J, Slomiany A. Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide. Biochem Mol Biol Int 1997; 42: 155-61.
28. 28 Hui WM, Lam SK, Ho J, et al. Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori. Am J Med 1989; 86: 60-5.
29. 29 Winter TA, Louw JA, Marks IN, et al. Effect of sucralfate on Helicobacter pylori and severity of gastritis in patients with duodenal ulcer. Scand J Gastroenterol Suppl 1995; 210: 85-8.
30. 30 Banerjee S, El OE, Mowat A, et al. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Gastroenterology 1996; 110: 717-24.
31. 31 Shorrock CJ, Garner A, Hunter AH, Crampton JR, Rees WD. Effect of bismuth subcitrate and sucralfate on rat duodenal and human gastric bicarbonate secretion in vivo. Gut 1990; 31: 26-31.
32. 32 Morris GP, Keenan CM, MacNaughton WK, Wallace JL, Williamson TE. Protection of rat gastric mucosa by sucralfate. Effects of luminal stasis and of inhibition of prostaglandins synthesis. Am J Med 1989; 86: 10-16.
33. 33 Nexo E, Poulsen SS. Does epidermal growth factor play a role in the action of sucralfate? Scand J Gastroenterol Suppl 1987; 127: 45-9.
34. 34 Itoh M, Imai S, Joh T, et al. Effect of epidermal growth factor in combination with sucralfate or omeprazole on the healing of chronic gastric ulcers in the rat. J Clin Gastroenterol 1990; 12: S187-91.
35. 35 Tarnawski A, Hollander D, Krause WJ, et al. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural, and functional assessment in the rat. Gastroenterology 1986; 90: 893-905.
36. 36 Nagashima R. Mechanisms of action of sucralfate. J Clin Gastroenterol 1981; 3: 117-27.
37. 37 Nagashima R. Development and characteristics of sucralfate. J Clin Gastroenterol 1981; 3: 103-10.
38. 38 Shea DT, Steel L, Montcalm E, Dubois A. Gastric protection by sucralfate. Role of mucus and prostaglandins. Gastroenterology 1986; 91: 660-6.
39. 39 Quadros E, Ramsamooj E, Wilson DE. Role of mucus and prostaglandins in the gastric mucosal protective actions of sucralfate against ethanol-induced injury in the rat. Am J Med 1987; 83: 19-23.
40. 40 de Bernard M, Papini E, de Filippis FV, et al. Low pH activates the vacuolating toxin of Helicobacter pylori, which becomes acid and pepsin resistant. J Biol Chem 1995; 270: 23937-40.